IP Library Granted Patent US 7,621,606
Granted Patent B2
US 7,621,606 · App. 10/228,296 · Granted Nov 24, 2009

Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,621,606
App. No.
10/228,296
Granted
Nov 24, 2009
Kind
B2
Abstract

The invention provides a method for effecting the trans-differentiation of a somatic cell, i.e., the conversion of a somatic cell of one cell type into a somatic cell of a different cell type. The method is practiced by culturing a somatic cell in the presence of at least one agent selected from the group consisting of (a) cytoskeletal inhibitors and (b) inhibitors of acetylation, and (c) inhibitors of methylation, and also culturing the cell in the presence of agents or conditions that induce differentiation to a different cell type. The method is useful for producing histocompatible cells for cell therapy.

Claims (15)

1. A method for converting a bovine fibroblast or a human fibroblast into a cell of neuronal cell type, the method comprising:(a) culturing the bovine fibroblast or the human fibroblast in the presence of 0.1 to 10 μg/ml cytochalasin B, and optionally, at least one inhibitor of acetylation, at least one inhibitor of methylation, or a mixture thereof, wherein the culturing is in the absence of a cell permeablizing agent; (b) culturing the fibroblast in the presence of an agent or a condition that induces differentiation of a multipotent cell capable of differentiating into a neuronal cell type into a neuronal cell type wherein step (b) is performed after step (a); and (c) identifying the cell of neuronal cell type from the culture of step (a) and step (b).

2. The method of claim 1 , further comprising culturing the fibroblast in serum-free medium before performing step (a) or prior to performing step (b).

3. The method of claim 1 , wherein the at least one inhibitor of acetylation is a deacetylase inhibitor.

4. The method of claim 1 , wherein the at least one inhibitor of methylation is a methylase inhibitor.

5. The method of claim 1 , further comprising culturing the fibroblast in serum-free medium prior to performing step (b).

6. The method of claim 1 , further comprising culturing the fibroblast is cultured in keratinocyte growth medium or neuro-progenitor growth medium before performing step (a) or prior to performing step (b).

7. The method of claim 1 , wherein the cell of neuronal cell type is identified by detection of a marker of cells of neuronal cell type.

8. The method of claim 7 , wherein the marker of cells of neuronal cell type is selected from the group consisting of TH, Nurr-1, Pax 3, Pax 5, Pax 8, En-1, FGFR3, GDNF, TUJ1, CalR, 4B3, and SMP.

9. The method of claim 1 , wherein the agent or the condition that induces differentiation into a cell of neuronal cell type is retinoic acid.

10. The method of claim 1 , wherein the agent or the condition that induces differentiation into the cell of neuronal cell type is selected from the group consisting of bFGF, FGF8, SHH, EGF, PDGF, T3, and CNTF.

11. A method for converting a bovine fibroblast or a human fibroblast into a cell of neuronal cell type, the method comprising:(a) culturing the bovine fibroblast or the human fibroblast in the presence of 0.1 to 10 μg/ml cytochalasin B, and optionally, at least one inhibitor of acetylation, at least one inhibitor of methylation, or a mixture thereof; (b) culturing the fibroblast in the presence of an agent or a condition that induces differentiation of a multipotent cell capable of differentiating into a neuronal cell type into a neuronal cell type wherein step (b) is performed after step (a); and (c) identifying the cell of neuronal cell type from the culture of step (a) and step (b) wherein: the culturing of step (a) is in the presence of the deacetylase inhibitor; the culturing of step (a) is in the presence of the methylase inhibitor; the cell of neuronal cell type is identified by detection of a marker of cells of neuronal cell type selected from the group consisting of TH, Nurr-1, Pax 3, Pax 5, Pax 8, En-1, FGFR3, GDNF, TUJ1, CalR, 4B3, and SMP; or the agent or the condition that induces differentiation into the cell of neuronal cell type of step (b) is retinoic acid.

12. The method of claim 11 , wherein the culturing of step (a) is in the presence of the deacetylase inhibitor.

13. The method of claim 11 , wherein the culturing of step (a) is in the presence of the methylase inhibitor.

14. The method of claim 11 , wherein the cell of neuronal cell type is identified by detection of a marker of cells of neuronal cell type selected from the group consisting of TH, Nurr-1, Pax 3, Pax 5, Pax 8, En-1, FGFR3, GDNF, TUJ1, CalR, 4B3, and SMP.

15. The method of claim 11 , wherein the agent or the condition that induces differentiation into the cell of neuronal cell type of step (b) is retinoic acid.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Nov 24, 2014
From: CAMOFI MASTER LDC; CAMHZN MASTER LDC
To: ADVANCED CELL TECHNOLOGY, INC.; MYTOGEN, INC.
Reel/Frame 034421/0863 →
SECURITY AGREEMENT Recorded Jan 25, 2013
From: ADVANCED CELL TECHNOLOGY, INC.; MYTOGEN, INC.
To: CAMOFI MASTER LDC; CAMHZN MASTER LDC
Reel/Frame 029698/0001 →